Physician profile
Lucia Maria Novak
NPI 1851361182
$473,310.27
in general payments reported to CMS, 2019-2025
48 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108K · 2022: $113K · 2023: $97K · 2024: $81K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Consulting Fee: $56K · Travel and Lodging: $52K · Food and Beverage: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $129,118.51 |
| Consulting Fee | $55,574.00 |
| Travel and Lodging | $51,538.20 |
| Food and Beverage | $11,909.08 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,250.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $221,590.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $138,467.14 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Sanofi-Aventis U.S. LLC | $73,800.10 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,453.89 | 2021-2025 | Jardiance |
| Medtronic, INC. | $7,251.67 | 2023-2024 | Minimed 780g, Minimed 770g, Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $4,590.01 | 2021-2025 | Gvoke Hypopen |
| Ascensia Diabetes Care US INC. | $1,533.71 | 2022-2024 | |
| Lilly USA, LLC | $1,365.25 | 2021-2025 | Mounjaro, Jardiance, Humulin |
| Eli Lilly and Company | $1,250.00 | 2022 | |
| Corcept Therapeutics | $925.61 | 2021-2025 | Korlym |
| Cequr Corporation | $384.11 | 2022-2024 | Cequr Simplicity |
| Beta Bionics, INC. | $285.94 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $262.11 | 2022-2025 | |
| Amgen INC. | $253.86 | 2022-2025 | Repatha, Prolia, Evenity |
| Astrazeneca Pharmaceuticals Lp | $217.36 | 2021-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucia Novak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.